Dr. Fonseca on FDA Approval of Daratumumab Triplets in Multiple Myeloma

FDA Approval of Frontline Daratumumab Plus VMP in Multiple MyelomaПодробнее

Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple MyelomaПодробнее

Dr. Landgren on Daratumumab Triplet in Relapsed MyelomaПодробнее

Relapsed/Refractory Myeloma: Daratumumab-Containing TripletsПодробнее

Analysis of Different Clinical Scenarios using Daratumumab | Rafael Fonseca, MD | Ash 2021Подробнее

What is Multiple Myeloma? | Dr. Rafael Fonseca, M.D. | The Patient StoryПодробнее

Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in MyelomaПодробнее

Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patternsПодробнее

Next steps in myeloma: quadruplets, immunotherapy, and replacing transplantПодробнее

Dr. Rafael Fonseca: A discussion about the utility of gene expression in Multiple MyelomaПодробнее

Copy of Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in MyelomaПодробнее

Daratumumab in the Treatment Landscape for MMПодробнее

MCRT Phoenix 2017: Determining the Right Therapy Strategy by Rafael Fonseca, MDПодробнее

The importance of anti-CD38 monoclonal antibodies for multiple myelomaПодробнее

Daratumumab in multiple myeloma: an overview of 3 key trialsПодробнее

Multiple Myeloma: Looking Ahead | Dr. Rafael Fonseca (5/5) | The Patient StoryПодробнее

Transplant vs bortezomib and LEN/DEX in multiple myelomaПодробнее

MRD Tests and Applications — Rafael Fonseca, MD | MCRT Webcast August 29 (2/4)Подробнее

Dr. Palumbo on Significance of Daratumumab Triplet in Multiple MyelomaПодробнее